61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

Contributed by: PR Newswire

Tags

ERA-Congress-Study

More Like This

UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes

MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults

EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

PR Newswire associated0

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

PR Newswire associated0

GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA

Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress